A Phase I, Open-Label, Randomized, Two-phase, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APL-1501 ER Tablets 2, APL1501 ER Tablets 3, and APL-1202 in Healthy Volunteers
Latest Information Update: 02 Nov 2021
Price :
$35 *
At a glance
- Drugs APL-1501 (Primary) ; Nitroxoline (Primary)
- Indications Bacterial infections; Bladder cancer; Prostate cancer
- Focus Adverse reactions
- Sponsors Asieris Pharmaceuticals
- 25 Jun 2021 Status changed from not yet recruiting to completed.
- 28 Oct 2020 According to an Asieris Pharmaceuticals media release, Australian regulatory authorities have approved its Phase I clinical trial of APL-1501.
- 28 Oct 2020 New trial record